These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37870738)
1. Antitumor activity of the new tyrphostin briva against BRAF Saleh K; Al Sakhen M; Kanaan S; Yasin S; Höpfner M; Tahtamouni L; Biersack B Invest New Drugs; 2023 Dec; 41(6):791-801. PubMed ID: 37870738 [TBL] [Abstract][Full Text] [Related]
2. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524 [TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF Hong SP; Ahn SK Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859 [TBL] [Abstract][Full Text] [Related]
4. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
5. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910 [TBL] [Abstract][Full Text] [Related]
6. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. Wang H; Quan H; Lou L Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078 [TBL] [Abstract][Full Text] [Related]
7. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618 [TBL] [Abstract][Full Text] [Related]
8. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495 [TBL] [Abstract][Full Text] [Related]
11. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. Wu Z; Huang M; Gong Y; Lin C; Guo W Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):355-361. PubMed ID: 29534162 [TBL] [Abstract][Full Text] [Related]
12. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684 [TBL] [Abstract][Full Text] [Related]
13. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638 [TBL] [Abstract][Full Text] [Related]
14. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849 [TBL] [Abstract][Full Text] [Related]
15. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544 [TBL] [Abstract][Full Text] [Related]
16. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. James J; Ruggeri B; Armstrong RC; Rowbottom MW; Jones-Bolin S; Gunawardane RN; Dobrzanski P; Gardner MF; Zhao H; Cramer MD; Hunter K; Nepomuceno RR; Cheng M; Gitnick D; Yazdanian M; Insko DE; Ator MA; Apuy JL; Faraoni R; Dorsey BD; Williams M; Bhagwat SS; Holladay MW Mol Cancer Ther; 2012 Apr; 11(4):930-41. PubMed ID: 22319199 [TBL] [Abstract][Full Text] [Related]
17. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
18. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733 [TBL] [Abstract][Full Text] [Related]
19. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. Hirschi B; Gallmeier E; Ziesch A; Marschall M; Kolligs FT Mol Cancer; 2014 May; 13():122. PubMed ID: 24885690 [TBL] [Abstract][Full Text] [Related]
20. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. Ma R; Xu L; Qu X; Che X; Zhang Y; Fan Y; Li C; Guo T; Hou K; Hu X; Drew L; Shen M; Cheung T; Liu Y Br J Cancer; 2018 May; 118(11):1453-1463. PubMed ID: 29755114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]